No Fee Unless We Win
(215) 866-2424

The Risk Of Pradaxa Injuries From Overdoses Or After Falls Continues To Be Studied

On the heels of the first Pradaxa lawsuits alleging bleeding injuries having been filed last month, two new scientific reports continue to raise questions about the safety of Pradaxa (Dabigatran).

The first report, put out by the Institute for Safe Medication Practices, notes that both of the major blood clotting inhibition medications, warfarin and Pradaxa, remain among the most dangerous outpatient treatments currently practiced in the United States, accounting for up to one-third of all emergency hospitalizations for drug side effects among the elderly. Moreover, and of particular concern, the ISMP report also says that Pradaxa was a suspected drug in over 800 cases of serious or fatal injuries recorded in the second quarter of 2011, including over 100 reported patient deaths potentially tied to Pradaxa.

The report singled out hemorrhages after accidents like falling and hemorrhagic strokes among elderly patients. These numbers unfortunately further confirm fears of patient advocates medical researchers that Pradaxa may be more likely to cause bleeding injuries than previously suspected, an outcome that may be tied to the lack of any available reversal agent for the medication.

A second report, a meta-analysis of studies published in the Annals of Internal Medicine, didwit did find that the injury rates attributed to warfarin might be lower than believed by the FDA when it approved Pradaxa. The study thus raises further questions about whether patients and physicians are fully informed about the true risks and benefits of Pradaxa. In the end, it may be that Pradaxa is no more effective in preventing ischemic strokes yet has higher rates of serious or fatal bleeding, including gastrointestinal and intracranial bleeding.

Given the severity of the problem, and the frequency with which we see blood thinning medication overdoses, our pharmaceutical product liability and medication error attorneys will continue to monitor the latest research on Pradaxa.

The studies are available here:

http://www.ismp.org/QuarterWatch/pdfs/2011Q2.pdf

http://archinte.ama-assn.org/cgi/content/short/archinternmed.2012.121

Share This Story
If you found the information provided by this article useful, consider sharing to your social media channels to help others in their search for reliable personal injury resources.
Get in Touch with Our Team Today
Contact us today by filling out the form below
or call us at (215) 866-2424 to speak with an attorney today.

Over $2 Billion Won
for Our Clients
(215) 866-2424
Philadelphia Office
1125 Walnut Street
Philadelphia, PA 19107
Follow Us

The information on this website is for general information purposes only. Nothing on this site should be taken as legal advice for any individual case or situation. This information is not intended to create, and receipt or viewing does not constitute, an attorney-client relationship.

Created By:

magnifierchevron-down